1 alpha(OH)D3 (ETALPHA) treatment and receptor studies in 16 patients with chronic and myeloproliferative disorders.
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1 alpha(OH)D3, up to 4 micrograms daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 micrograms daily of 1 alpha(OH)D3 for a prolonged period up to 17 wk. The treatment with 1 alpha (OH)D3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH)2D3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1 alpha(OH)D3 varied individually, but was in the range of 2-4 micrograms daily.
D006801:Humans; D006887:Hydroxycholecalciferols / Q000378:metabolism / Q000627:therapeutic use*; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D007951:Leukemia, Myeloid / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D008214:Lymphocytes / Q000648:ultrastructure; D009196:Myeloproliferative Disorders / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D011955:Receptors, Drug / Q000378:metabolism*
D006887:Hydroxycholecalciferols; D011955:Receptors, Drug; C008088:alfacalcidol